HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers.
CAT No: R1416
CAS No:160790-21-6
Synonyms/Alias:HER2/neu (654-662) GP2;160790-21-6;GP-2 HER2-derived, hla-a2+ restricted peptide;GP2 peptide;UNII-FQA52PV28G;FQA52PV28G;GP-2;(2S)-2-[[(2S,3S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid;L-Isoleucyl-L-isoleucyl-L-seryl-L-alanyl-L-valyl-L-valylglycyl-L-isoleucyl-L-leucine;L-Leucine, L-isoleucyl-L-isoleucyl-L-seryl-L-alanyl-L-valyl-L-valylglycyl-L-isoleucyl-;HY-P1855;NCGC00167173-01;DA-74094;MS-31637;CS-0096586;G12931;(2S,5S,11S,14S,17S,20S,23S,26S,27S)-26-amino-5,23-di-sec-butyl-20-(hydroxymethyl)-2-isobutyl-11,14-diisopropyl-17,27-dimethyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazanonacosan-1-oic acid;
HER2/neu (654-662) GP2 is a synthetic peptide corresponding to a highly immunogenic epitope derived from the human epidermal growth factor receptor 2 (HER2/neu) protein, specifically encompassing amino acids 654 to 662. As a well-characterized peptide fragment, GP2 is widely utilized in immunological and oncological research for its relevance to HER2/neu, a receptor frequently overexpressed in various cancers. Its defined sequence and proven immunogenicity make it a valuable tool for studies investigating antigen-specific immune responses, peptide-MHC interactions, and the molecular underpinnings of tumor immunology. The unique properties of this peptide enable its integration into a broad spectrum of experimental workflows, facilitating both basic and applied research in cellular immunity and cancer biology.
Epitope mapping: Researchers employ the GP2 peptide in epitope mapping studies to precisely define the antigenic determinants recognized by T cells in the context of HER2/neu-associated malignancies. By presenting this peptide to immune effector cells, investigators can delineate the specificity of T cell receptors and characterize the immunodominant regions of the HER2/neu protein. These insights are critical for understanding the immune recognition landscape in tumor environments and for identifying key peptide motifs that drive antigen-specific immune responses.
MHC binding and peptide presentation assays: GP2 serves as a model peptide in major histocompatibility complex (MHC) binding studies, particularly in the context of HLA-A2 molecules. Its well-established affinity for certain MHC class I alleles allows for the investigation of peptide loading, stability, and presentation mechanisms. These assays are instrumental in elucidating how tumor-associated antigens are processed and displayed on the cell surface, which is pivotal for the development of antigen-targeted immunotherapies and for advancing knowledge of immune surveillance processes.
T cell activation research: The GP2 peptide is frequently utilized in functional assays designed to assess cytotoxic T lymphocyte (CTL) activation, proliferation, and cytokine production. By pulsing antigen-presenting cells with this peptide, researchers can stimulate and monitor HER2/neu-specific T cell responses in vitro. These experiments are essential for dissecting the cellular and molecular mechanisms governing anti-tumor immunity, enabling the evaluation of T cell functionality, specificity, and the potential for immune modulation in cancer models.
Peptide-based vaccine development: In preclinical immunology and vaccine design, the GP2 peptide is incorporated into experimental formulations to evaluate its capacity to elicit targeted immune responses. Its use as a defined antigenic component allows for the systematic assessment of adjuvant systems, delivery platforms, and immunization protocols. Such studies support the rational design and optimization of peptide-based vaccines, providing foundational data on immunogenicity, antigen processing, and immune memory in the context of HER2/neu-driven oncogenesis.
Immunological assay standardization: As a reference peptide with well-characterized immunogenic properties, GP2 is employed in the standardization and validation of immunological assays, including ELISPOT, intracellular cytokine staining, and flow cytometry-based detection of antigen-specific T cells. Its reproducible activity and defined sequence make it an ideal positive control for assay calibration, quality control, and benchmarking across different experimental platforms. This application ensures the reliability and comparability of immunological data, thereby supporting robust experimental design and interpretation in immune monitoring studies.
1. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
4. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More